Abstract
A common feature of solid tumors, including glioblastoma multiforme (GBM), is mitochondrial dysfunction. However, it is reported that the current standard of anti-GBM therapies may potentiate mitochondrial damage and, in effect, support the aggressive character of cancer. As mitochondria are implicated in the modulation of cellular drug sensitivity and chemoresistance mechanisms, activation-stressed mitochondria in GBM cells may represent a new target for anti-GBM therapy that is nontoxic for normal cells. As mitochondria are possible targets for antidepressant drugs used as adjuvant therapy in patients with GBM, we examined their influence on mitochondrial volume and activity, reactive oxygen species level, extracellular lactate concentration, and p65 NF-κB gene expression in GBM cells. Our investigation showed, for the first time, that tricyclic antidepressants, imipramine and amitriptyline, partially reverse GBM abnormalities. In the light of reported studies, the mitochondrial disturbance observed in glioma cells is a dynamic process that can be reversed or silenced. Moreover, imipramine and amitriptyline are attractive cellular metabolic modulators and can potentially be used to restoring a proper function of mitochondria ...Continue Reading
References
Jan 1, 1982·Psychopharmacology·R K Glotzbach, S H Preskorn
Nov 1, 1995·Journal of Clinical Epidemiology·A B Steingart, M Cotterchio
Jan 22, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Bogusława BudziszewskaWładysław Lasoń
Jul 16, 2004·Seminars in Radiation Oncology·Peter Vaupel
Feb 8, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Olga J G SchiepersMichael Maes
Jul 21, 2006·The British Journal of Radiology·A Y IsaJ J Homer
Sep 30, 2006·Molecular Human Reproduction·Mark SullivanSania Latif
Jan 22, 2008·Seminars in Cancer Biology·Geoffrey J PilkingtonSamantha A Murray
Mar 29, 2008·The Journal of Biological Chemistry·Benedikt Westermann
Apr 23, 2008·Current Protocols in Neuroscience·R RibaudoN Sacchi
Jun 13, 2008·Journal of Neuroimmunology·Alice GuyonJean-Louis Nahon
Jul 22, 2008·Neuropharmacology·Jaegyu HwangKyoungho Suk
Nov 27, 2008·Neuro-oncology·Fusun BaumannPeter Hau
Aug 26, 2009·Current Drug Targets·Michel BourinMartine Hascoët
Aug 26, 2009·The International Journal of Biochemistry & Cell Biology·Gabriel Arismendi-Morillo
Apr 27, 2010·Journal of Biomedical Science·Anna M CzarneckaAndrzej Kukwa
Jan 25, 2011·Nature Reviews. Cancer·Rob A CairnsTak W Mak
Sep 6, 2011·Biochemical and Biophysical Research Communications·Seung-Hyun JeonSoon Young Shin
Jul 31, 2012·Toxicology Letters·Jana Hroudová, Zdeněk Fišar
Feb 2, 2013·Life Sciences·Luciana Romina Frick, Maximiliano Rapanelli
Sep 14, 2013·Journal of Neurology, Neurosurgery, and Psychiatry·Alasdair G RooneyRobin Grant
Sep 26, 2013·Trends in Cell Biology·Kristopher A SarosiekAnthony Letai
Nov 19, 2013·PloS One·Braden C McFarlandSusan E Nozell
Apr 15, 2014·Journal of Neuro-oncology·Ruth F DeightonJames McCulloch
Jul 22, 2014·Journal of Korean Medical Science·So Hyun BaeChae-Yong Kim
Dec 7, 2014·General Hospital Psychiatry·Jan JaraczJoanna Hauser
Jan 16, 2015·Cell Death & Disease·E SingerL Soroceanu
Mar 15, 2015·Drug Discovery Today·Tariq A BhatDhyan Chandra
Jul 17, 2015·PLoS Biology·Robert HaasClaudio Mauro
Dec 18, 2015·BBA Clinical·Joshua A Hess, Mohamad K Khasawneh
Mar 19, 2016·Scientific Reports·Keiichiro HayashiHideki Matsui
Apr 27, 2016·British Journal of Cancer·Anton PottegårdDavid Gaist
Jun 14, 2016·Brain Tumor Pathology·Kenta MasuiPaul S Mischel
Jun 25, 2016·International Journal of Molecular Sciences·Mariagrazia RinaldiGerardo Caruso
Aug 3, 2016·European Journal of Cancer Care·A M Bielecka, E Obuchowicz
May 14, 2017·Cancer Chemotherapy and Pharmacology·Anna M Bielecka-WajdmanEwa Obuchowicz